151 related articles for article (PubMed ID: 32535722)
1. Landscape of Germline Genetic Variants in AGT, MGMT, and TP53 in Mexican Adult Patients with Astrocytoma.
Carlos-Escalante JA; Gómez-Flores-Ramos L; Bian X; Perdomo-Pantoja A; de Andrade KC; Mejía-Pérez SI; Cacho-Díaz B; González-Barrios R; Reynoso-Noverón N; Soto-Reyes E; Sánchez-Correa TE; Guerra-Calderas L; Yan C; Chen Q; Castro-Hernández C; Vidal-Millán S; Taja-Chayeb L; Gutiérrez O; Álvarez-Gómez RM; Gómez-Amador JL; Ostrosky-Wegman P; Mohar-Betancourt A; Herrera-Montalvo LA; Corona T; Meerzaman D; Wegman-Ostrosky T
Cell Mol Neurobiol; 2021 Aug; 41(6):1285-1297. PubMed ID: 32535722
[TBL] [Abstract][Full Text] [Related]
2. Deep DNA sequencing of MGMT, TP53 and AGT in Mexican astrocytoma patients identifies an excess of genetic variants in women and a predictive biomarker.
Carlos-Escalante JA; Mejía-Pérez SI; Soto-Reyes E; Guerra-Calderas L; Cacho-Díaz B; Torres-Arciga K; Montalvo-Casimiro M; González-Barrios R; Reynoso-Noverón N; Ruiz-de la Cruz M; Díaz-Velásquez CE; Vidal-Millán S; Álvarez-Gómez RM; Sánchez-Correa TE; Pech-Cervantes CH; Soria-Lucio JA; Pérez-Castillo A; Salazar AM; Arriaga-Canon C; Vaca-Paniagua F; González-Arenas A; Ostrosky-Wegman P; Mohar-Betancourt A; Herrera LA; Corona T; Wegman-Ostrosky T
J Neurooncol; 2023 Jan; 161(1):165-174. PubMed ID: 36525166
[TBL] [Abstract][Full Text] [Related]
3. MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.
Groenendijk FH; Taal W; Dubbink HJ; Haarloo CR; Kouwenhoven MC; van den Bent MJ; Kros JM; Dinjens WN
J Neurooncol; 2011 Feb; 101(3):405-17. PubMed ID: 20593220
[TBL] [Abstract][Full Text] [Related]
4. Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts.
Jones DT; Mulholland SA; Pearson DM; Malley DS; Openshaw SW; Lambert SR; Liu L; Bäcklund LM; Ichimura K; Collins VP
Acta Neuropathol; 2011 Jun; 121(6):753-61. PubMed ID: 21327941
[TBL] [Abstract][Full Text] [Related]
5. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
Li X; Wei J; Liu Y; Li P; Fan L; Wang Y; Li M; Zhao D; Yu Z; Ye J; Guo Y; Yan Q; Guo S; Wang Z
Sci Rep; 2017 Oct; 7(1):13038. PubMed ID: 29026176
[TBL] [Abstract][Full Text] [Related]
6. ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.
Shao LW; Pan Y; Qi XL; Li YX; Ma XL; Yi WN; Zhang J; Zhong YF; Chang Q
Histol Histopathol; 2016 Jan; 31(1):103-14. PubMed ID: 26395639
[TBL] [Abstract][Full Text] [Related]
7. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
[TBL] [Abstract][Full Text] [Related]
8. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J
Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas.
Grasbon-Frodl EM; Kreth FW; Ruiter M; Schnell O; Bise K; Felsberg J; Reifenberger G; Tonn JC; Kretzschmar HA
Int J Cancer; 2007 Dec; 121(11):2458-64. PubMed ID: 17691113
[TBL] [Abstract][Full Text] [Related]
10. Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.
Huang L; Jiang T; Yuan F; Li GL; Cui Y; Liu EZ; Wang ZC
Neuropathol Appl Neurobiol; 2009 Aug; 35(4):367-379. PubMed ID: 19019173
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
12. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
[TBL] [Abstract][Full Text] [Related]
13. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
van den Bent MJ; Gravendeel LA; Gorlia T; Kros JM; Lapre L; Wesseling P; Teepen JL; Idbaih A; Sanson M; Smitt PA; French PJ
Clin Cancer Res; 2011 Nov; 17(22):7148-55. PubMed ID: 21914791
[TBL] [Abstract][Full Text] [Related]
14. Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma.
Marucci G; Morandi L
J Neurooncol; 2011 Nov; 105(2):397-400. PubMed ID: 21626073
[TBL] [Abstract][Full Text] [Related]
15. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
Minniti G; Scaringi C; Arcella A; Lanzetta G; Di Stefano D; Scarpino S; Bozzao A; Pace A; Villani V; Salvati M; Esposito V; Giangaspero F; Enrici RM
J Neurooncol; 2014 Jun; 118(2):377-383. PubMed ID: 24748470
[TBL] [Abstract][Full Text] [Related]
16. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue.
Cankovic M; Mikkelsen T; Rosenblum ML; Zarbo RJ
Lab Invest; 2007 Apr; 87(4):392-7. PubMed ID: 17260000
[TBL] [Abstract][Full Text] [Related]
17. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma.
Christmann M; Nagel G; Horn S; Krahn U; Wiewrodt D; Sommer C; Kaina B
Int J Cancer; 2010 Nov; 127(9):2106-18. PubMed ID: 20131314
[TBL] [Abstract][Full Text] [Related]
18. MGMT gene promoter methylation in pediatric glioblastomas.
Srivastava A; Jain A; Jha P; Suri V; Sharma MC; Mallick S; Puri T; Gupta DK; Gupta A; Sarkar C
Childs Nerv Syst; 2010 Nov; 26(11):1613-8. PubMed ID: 20585787
[TBL] [Abstract][Full Text] [Related]
19. [IDH1 mutation and MGMT expression in astrocytoma and the relationship with prognosis after radiotherapy].
Jiang M; Dong X; Li J; Li J; Qi J
Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):668-72. PubMed ID: 25567592
[TBL] [Abstract][Full Text] [Related]
20. MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.
Mulholland S; Pearson DM; Hamoudi RA; Malley DS; Smith CM; Weaver JM; Jones DT; Kocialkowski S; Bäcklund LM; Collins VP; Ichimura K
Int J Cancer; 2012 Sep; 131(5):1104-13. PubMed ID: 22020830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
